

ASX Announcement

Chief Medical Officer Appointment

- Dr Ajay Duggal appointed interim Chief Medical Officer of Race Oncology, effective 14 November 2022
- Dr Duggal succeeds Dr David Fuller, effective 11 November 2022

11 November 2022 – Race Oncology Ltd (ASX: RAC) advises that Dr David Fuller has resigned as Chief Medical Officer (CMO), effective 11 November 2022, to take up the role of CMO at Aucentra Therapeutics.

Dr Fuller is succeeded by Dr Ajay Duggal of Adnovate Clinical who commences on 14 November 2022 as interim CMO, pending appointment of a new full time CMO. The interim CMO will work closely with Race's executive and clinical team who have been intimately involved in all aspects of the design and implementation of Race's clinical programs. All clinical programs are expected to continue without disruption.

CEO and Managing Director Phillip Lynch of Race Oncology commented, *"We're grateful to David for his strong domain expertise and dedication as we have grown Race. He has successfully led the Race clinical team in implementing our clinical programs both in Australia and overseas and leaves us in a very strong strategic position. We wish David all the best in his new role with Aucentra Therapeutics."*

Dr David Fuller commented, *"I have enjoyed the opportunity to work with the Race team progressing the 3 pillar strategy. I wish the company every success as it moves ahead."*

The recruitment of a permanent CMO is being undertaken by Coulter Partners, a specialised international pharma/biotech executive recruitment firm who were appointed after a diligent evaluation of capability and requirements by Race.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.



In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au